Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John L Johnson

Showing results (101-110 of 108) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 108 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 17, 2021
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose RifapentineAnthony T Podany, Michelle Pham, Erin Sizemore, et al.
Immunity|May 1, 2020
The Transcription Factor T-bet Resolves Memory B Cell Subsets with Distinct Tissue Distributions and Antibody Specificities in Mice and HumansJohn L Johnson, Rebecca L Rosenthal, James J Knox, et al.
Tuberculosis (Edinburgh, Scotland)|August 22, 2019
Distinct serum biosignatures are associated with different tuberculosis treatment outcomesKatharina Ronacher, Novel N Chegou, Léanie Kleynhans, et al.
Nature Communications|October 31, 2024
Risk-stratified treatment for drug-susceptible pulmonary tuberculosisVincent K Chang, Marjorie Z Imperial, Patrick P J Phillips, et al.
American Journal of Respiratory and Critical Care Medicine|February 15, 2023
A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical TrialsEkaterina V Kurbatova, Patrick P J Phillips, Susan E Dorman, et al.
Immunity|December 1, 2021
Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responsesMohamad-Gabriel Alameh, István Tombácz, Emily Bettini, et al.
The New England Journal of Medicine|May 5, 2021
Four-Month Rifapentine Regimens with or without Moxifloxacin for TuberculosisSusan E Dorman, Payam Nahid, Ekaterina V Kurbatova, et al.
Contemporary Clinical Trials|January 26, 2020
High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trialSusan E Dorman, Payam Nahid, Ekaterina V Kurbatova, et al.
Pageof 11

Showing results (101-110 of 108) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 108 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 17, 2021
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose RifapentineAnthony T Podany, Michelle Pham, Erin Sizemore, et al.
Immunity|May 1, 2020
The Transcription Factor T-bet Resolves Memory B Cell Subsets with Distinct Tissue Distributions and Antibody Specificities in Mice and HumansJohn L Johnson, Rebecca L Rosenthal, James J Knox, et al.
Tuberculosis (Edinburgh, Scotland)|August 22, 2019
Distinct serum biosignatures are associated with different tuberculosis treatment outcomesKatharina Ronacher, Novel N Chegou, Léanie Kleynhans, et al.
Nature Communications|October 31, 2024
Risk-stratified treatment for drug-susceptible pulmonary tuberculosisVincent K Chang, Marjorie Z Imperial, Patrick P J Phillips, et al.
American Journal of Respiratory and Critical Care Medicine|February 15, 2023
A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical TrialsEkaterina V Kurbatova, Patrick P J Phillips, Susan E Dorman, et al.
Immunity|December 1, 2021
Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responsesMohamad-Gabriel Alameh, István Tombácz, Emily Bettini, et al.
The New England Journal of Medicine|May 5, 2021
Four-Month Rifapentine Regimens with or without Moxifloxacin for TuberculosisSusan E Dorman, Payam Nahid, Ekaterina V Kurbatova, et al.
Contemporary Clinical Trials|January 26, 2020
High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trialSusan E Dorman, Payam Nahid, Ekaterina V Kurbatova, et al.
Pageof 11